
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte Inc is positioned favorably due to its successful Phase 3 clinical trials and anticipated regulatory support, which could enhance the company’s market valuation and likelihood of commercial success, irrespective of ongoing Phase 2 data. The firm's peak revenue estimate has been slightly adjusted upward to $6.8 billion for 2040, reflecting a positive outlook on market adoption and dynamics of its flagship product VAX-31, set to launch in 2028. The extensive market opportunity for pneumococcal conjugate vaccines, particularly with new recommendations for adults over 50 by the ACIP, underscores Vaxcyte's potential for substantial growth, driven further by positive clinical outcomes expected from its ongoing trials.
Bears say
Vaxcyte’s stock outlook is negatively impacted by the underwhelming expectations surrounding the VAX-24 Phase 2 trial in infants, which may dampen investor confidence in the company’s potential within the larger pediatric vaccine market. Additionally, the prevailing tougher stance on vaccines from regulatory authorities adds to the uncertainty faced by the company, potentially complicating its market entry and acceptance for its vaccine candidates. Furthermore, Vaxcyte faces inherent risks associated with clinical trials, including the possibility of failing to demonstrate safety and efficacy, which could severely limit its commercial prospects.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares